Does Ohio Medicaid Cover Wegovy or Zepbound? What the Unified Drug List Says

No, not for weight loss. Ohio’s Medicaid rule lists drugs for the treatment of obesity as non-covered, and Zepbound does not appear on the state’s October 2026 drug list at all.^[1][2] Wegovy is covered for two other uses, reducing heart risk in people without diabetes and treating the liver disease MASH.^[1]

Why doesn't Ohio Medicaid cover GLP-1s for weight loss?

Federal Medicaid law does not require states to cover weight-loss drugs, and Ohio left them out in its administrative code, which lists obesity drugs first among its non-covered categories.^[2][10] A notice from Ohio Medicaid’s pharmacy benefit manager, effective December 8, 2025, applied the same line to the preferred diabetes GLP-1s, requiring a type 2 diabetes diagnosis and saying coverage is not available for uses such as prediabetes or weight loss.^[4]

Ohio’s drug list is unified, so the answer does not change by plan: the same document covers fee-for-service and every managed care plan.^[1] Changing from one Ohio Medicaid plan to another will not open up a weight-loss route.

Does Ohio Medicaid cover Wegovy for heart disease?

Yes. In January 2026, the department proposed and its pharmacy committee backed a new category called Metabolic Modifiers, with a subcategory for GLP-1s used for non-obesity indications, and Wegovy is its only drug.^[1][3] The list excludes the 7.2 mg injection.^[1] A request needs all of the following:^[1]

• An adult with a BMI at or above 27.
• Chart notes showing a past heart attack, a past stroke, or symptomatic peripheral artery disease, meaning claudication with an ankle-brachial index below 0.85 at rest, a revascularization procedure or an amputation from atherosclerotic disease.
• No type 1 or type 2 diabetes. Those patients are sent to the diabetes class.
• Standard heart treatment documented, such as an antiplatelet drug, a lipid-lowering drug and a blood pressure drug, or the reason a person cannot take them.
• No other GLP-1 at the same time.

Approval lasts 180 days.^[1] The diabetes exclusion is sharper than the label, which sets no such bar for the heart use, and it is what makes the class odd: a person with diabetes and a past heart attack has to go through the diabetes route, starting with older preferred drugs.^[1][8]

Why does renewal require 5% weight loss?

Ohio’s renewal for the heart route asks for chart notes showing at least 5% weight loss from baseline, along with claims showing at least 80% of days covered.^[1] The state does not explain the rule in the list. It sits awkwardly with the trial evidence: a prespecified analysis of 17,604 people in SELECT concluded that semaglutide’s heart protection was independent of baseline adiposity and weight loss.^[7] That analysis was funded by the drug’s maker. Our piece on what weight loss did and did not predict walks through the numbers.

In practice, someone who stays on Wegovy for 180 days, takes the standard heart medicines and loses 4% could face a denial. If that happens, ask the prescriber to put the full cardiovascular record into the renewal, and start planning before the approval ends.

Does Ohio Medicaid cover Wegovy for MASH?

Yes, for adults with noncirrhotic MASH and stage F2 or F3 fibrosis, confirmed by a liver biopsy in the prior 24 months or by two noninvasive measures, such as a Fibrosis-4 index or Enhanced Liver Fibrosis blood test plus a liver stiffness scan.^[1] The prescriber attests to diet, activity and optimized care for related heart conditions, and the person cannot be on another MASH drug such as resmetirom or another GLP-1.^[1] Renewal is demanding: 5% weight loss, 80% of days covered, and resolution of steatohepatitis without worse fibrosis, or one stage of fibrosis improvement without worse steatohepatitis.^[1] For background on the evidence, see GLP-1s and fatty liver.

Does Ohio Medicaid cover Zepbound for sleep apnea?

Not on the current list. Zepbound appears nowhere in the October 2026 Unified Preferred Drug List, and the Metabolic Modifier class names only Wegovy.^[1] Sleep apnea is a labeled use of Zepbound in adults with obesity, and some programs and insurers pay for it, but the Ohio list has no such route.^[9] A prescriber can ask the plan how an off-list request would be handled, though we found no Ohio criteria for one.

Are Ozempic and Mounjaro covered for diabetes in Ohio?

Yes, but they are not first in line. The preferred GLP-1s are Trulicity, Victoza, liraglutide, Byetta and exenatide, and a claim requires a type 2 diabetes diagnosis.^[1][4] Ozempic, Mounjaro and Rybelsus are non-preferred, with detailed criteria:^[1]

1. At least 120 days of inadequate response with three preferred drugs in the category, including two used together and doses taken to the maximum tolerated.
2. A current A1C from the past six months, and a patient-specific goal if the target is below 7%.
3. For anyone who stopped a GLP-1 because of stomach problems, 30 days of tried fixes: dietary changes, antiemetic prescriptions and a dose adjustment.
4. For Mounjaro, an A1C above 7% and 120 days on Ozempic, or a documented reason Ozempic cannot be used.

Approval runs for 365 days, and renewal needs a recent A1C showing improvement from baseline.^[1] Someone already taking Mounjaro should check the current status with the plan before a renewal date.

How do you appeal an Ohio Medicaid denial?

• Plan appeal. Managed care members have 60 calendar days from the notice.^[6]
• State hearing. You then have 90 calendar days after the plan’s appeal decision is mailed.^[5] Fee-for-service members also get 90 days from a notice of action.^[5]

Because obesity drugs are excluded by rule, an appeal asking for weight-loss coverage is unlikely to win. Appeals have more room when the record was incomplete for heart disease, MASH or a non-preferred diabetes drug. Our guide to prior authorization and appeals shows what to send, and the state Medicaid checker compares other states.

What are the options without Ohio Medicaid coverage?

Self-pay is the usual route, and Lilly’s savings card excludes government programs.^[11] Prices in the figures we track are $349 a month for most Wegovy pen doses from Novo Nordisk, and from $299 at the starting dose up to $449 at higher doses for Lilly’s Zepbound KwikPen or vial.^[11][12] Check whether each offer accepts Medicaid members. The guide to the lowest GLP-1 prices without insurance compares them, and our national overview of Medicaid coverage for Zepbound shows how Ohio compares.